Clinigen Group Given Buy Rating at Numis Securities Ltd (CLIN)
Clinigen Group (LON:CLIN)‘s stock had its “buy” rating reiterated by Numis Securities Ltd in a research note issued on Wednesday, StockRatingsNetwork reports. They currently have a GBX 485 ($7.77) target price on the stock. Numis Securities Ltd’s price target points to a potential upside of 20.35% from the company’s current price.
A number of other firms have also recently commented on CLIN. Analysts at Investec downgraded shares of Clinigen Group (LON:CLIN) from a “buy” rating to a “hold” rating in a research note to investors on Thursday, August 1st. They now have a GBX 313 ($5.01) price target on the stock, up previously from GBX 290 ($4.65).
Clinigen Group (LON:CLIN) opened at 430.00 on Wednesday. Clinigen Group has a 52 week low of GBX 195.00 and a 52 week high of GBX 405.00. The stock has a 50-day moving average of GBX 376.8 and a 200-day moving average of GBX 302.7.
Clinigen Group plc (LON:CLIN) is a specialty pharmaceuticals and services business company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.